NEO’s cancer-testing comeback is gaining real traction

The thesis

NeoGenomics is showing a cleaner growth story in 2026: first-quarter revenue rose 11% to $187 million, clinical revenue climbed 14%, and the company lifted full-year 2026 revenue guidance to $797 million-$803 million.[1][2] The newer products are doing the heavy lifting. Management said RADAR ST had its full clinical launch, PanTracer Liquid won MolDX approval in March, and next-generation sequencing revenue grew 26%, now making up about one-third of clinical revenue.[2][7] That matters because it suggests NeoGenomics is selling more of the higher-value cancer tests investors have wanted to see. The next test is Q2 results on July 28, 2026.[3][4]

Everyone wishes they'd bought Nvidia early. Here's how to spot the next one.

The biggest winners of the last decade had one thing in common. Our data follows those exact moves — and turns them into 10 names to watch right now.

The big names in the AI, Space, Nuclear and Robotics race. The window to get in early is closing fast. Don't wait.

See the top 10 stocks now — free ›

💡 Why this matters

If you care about the genomics trend, NEO is a simple way to play more cancer testing without betting on a tiny startup. The story is easy to understand: doctors are using more advanced lab tests to help spot, classify, and track cancer, and NeoGenomics is trying to become the go-to one-stop shop for that work.[2][11] For retail investors, the appeal is that this is tied to a real healthcare need, not a fad. The risk is that it is still a mid-sized business trying to prove it can turn faster test growth into steadier profits.[9][11]

▲ Catalysts

+ Q2 2026 earnings are set for July 28, 2026, which should show whether first-quarter momentum held.[3][4]
+ PanTracer Liquid got MolDX approval in March 2026, opening the door to more reimbursed cancer testing.[2]
+ RADAR ST had its full clinical launch in 2026, adding another newer product to the mix.[2]
+ NeoGenomics raised 2026 revenue guidance to $797 million-$803 million after Q1 strength.[1][2]
+ NeoGenomics launched an FDA-approved PTEN IHC companion diagnostic for prostate cancer in 2026.[4][12]

▼ Risks

! The company is still losing money at the operating level, so growth has not fully turned into durable profit.[9]
! Leadership turnover is a real concern, with recent executive departures flagged as the main caution.[9]
! A lot of the bull case depends on newer tests gaining traction quickly, and that can take time.[2][7]
! Competition is intense in cancer diagnostics, so NeoGenomics has to keep proving it can win business and keep margins improving.[11]

🎯 One thing to take away

NEO looks like a real turnaround story, not just a hype name. In 2026, sales are growing, the company raised its full-year outlook, and newer cancer tests like RADAR ST and PanTracer Liquid are starting to matter.[1][2] That is the good part. The caution flag is that NeoGenomics is still working through profit pressure and leadership changes, so this is not a clean, low-risk story.[9] If you want exposure to cancer diagnostics and can tolerate some bumps, this is one to watch closely. The July 28 earnings report will tell us whether the recent progress is sticking.[3][4]

Data sources & methodology

All figures derive from official, public-domain government filings. Read our methodology for how we collect, process and score this data. See the methodology →

TZ Researched & published by TradesZ Research

Want our premium picks too?

Pro subscribers get our strongest pre-pop ideas + real-time buy-zone alerts.

Thinking about NEO?

Our data likes 10 other stocks even more right now — under-the-radar names we believe have monster upside potential. Get the free list before the crowd catches on.

Show me the 10 stocks — free →

Free · no credit card · unsubscribe in one click

Not investment advice. We share research and analyses for educational purposes. Investing in stocks involves risk, including possible loss of capital. Always do your own research.